Molecular Tests Discriminate Prognosis in Normal Karyotype AML

    loading  Checking for direct PDF access through Ovid



Mutations in several genes may refine prognosis in normal karyotype AML. The mutational status of the fms-related tyrosine kinase gene (FLT3), the CCAAT/enhancer binding protein gene (CEPBA), the mixed lineage leukemia gene (MLL) and neuroblastoma RAS viral oncogene homolog (NRAS) were evaluated in 663 normal karyotype AML patients under 60 years of age. Favorable prognostic groups included mutations for NPM1 mutations without a FLT-3 ITD, CEBPA, and MLL. Allogeneic transplant appeared beneficial in the largest prognostically unfavorable groups having with an FLT-3 ITD.


R. Schlenk, et al. for the German-Austrian Acute Myeloid Leukemia Study Group. N Engl J Med. 2008;358:1909-1918.

Related Topics

    loading  Loading Related Articles